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Abstract
Prostate cancer (PCa) bone metastases have long been believed to be osteoblastic because of bone remodeling leading to
the formation of new bone. However, recent studies have shown increased osteolytic activity in the beginning stages of PCa
bone metastases, suggesting that targeting both osteolytic and osteoblastic mediators would likely inhibit bone
remodeling and PCa bone metastasis. In this study, we found that PCa cells could stimulate differentiation of osteoclasts
and osteoblasts through the up-regulation of RANKL, RUNX2 and osteopontin, promoting bone remodeling. Interestingly,
we found that formulated isoflavone and 3,39-diindolylmethane (BR-DIM) were able to inhibit the differentiation of
osteoclasts and osteoblasts through the inhibition of cell signal transduction in RANKL, osteoblastic, and PCa cell signaling.
Moreover, we found that isoflavone and BR-DIM down-regulated the expression of miR-92a, which is known to be
associated with RANKL signaling, EMT and cancer progression. By pathway and network analysis, we also observed the
regulatory effects of isoflavone and BR-DIM on multiple signaling pathways such as AR/PSA, NKX3-1/Akt/p27, MITF, etc.
Therefore, isoflavone and BR-DIM with their multi-targeted effects could be useful for the prevention of PCa progression,
especially by attenuating bone metastasis mechanisms.
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Introduction
Prostate cancer (PCa) is a common cancer and the second
leading cause of cancer related deaths in men in the United
States with an estimated 241,740 new cases and 28,170 deaths
are expected in 2012 [1]. The high rate of mortality of PCa is
mainly due to the development of metastasis. PCa commonly
exhibits its progressive features through the cascades of
androgen dependence to castrate resistance with eventual
metastasis. Even though the PCa may be considered localized
to the prostate, there is still a 15% to 20% incidence of
subsequent metastasis [2]. It has been reported that 35% of
patients with PCa develop hematogeneous metastases and that
bone metastasis of PCa is the most frequent (,90%) among the
hematogeneous metastases [3]. PCa bone metastases have long
been believed to be osteoblastic because of the formation of new
bone. Therefore, targeting osteoblastic molecules such as
endothelin-1, BMP, and Wnt signaling has been considered as
strategies for inhibiting PCa bone metastasis [2]. However,
recent studies found increased osteolytic activity in the
beginning stages of PCa bone metastases [4,5]. Several growth
factors were found to be released from the bone matrix during
degradation when PCa cells metastasized to the bone.
Moreover, cancer cells could spread to the bone and utilize
the local cytokine machinery to stimulate osteoclastogenesis,
resulting in bone resorption and cancer cell growth [6]. These
findings suggest that bone remodeling including osteolytic and
osteoblastic processes occurs during PCa bone metastasis and, in
turn, favors the growth of PCa cells in the newly formed bone.
Therefore, molecular targeting of both osteolytic and osteoblas-
tic mediators would likely inhibit bone remodeling, which could
become a newer therapeutic strategy for the inhibition of PCa
bone metastasis.
To inhibit osteolytic process, several strategies have been
developed including the use of bisphosphonates and targeting
the biological regulators of osteoclastogenesis, such as osteo-
protegerin (OPG), receptor activator of nuclear factor-kB
(RANK) and receptor activator of nuclear factor-kBl i g a n d
(RANKL). The most important cytokine machinery, which is
involved in bone remodeling and PCa bone metastasis, is OPG/
RANK/RANKL signaling [7,8]. RANKL is expressed by
osteoblasts, and it is necessary and sufficient for osteoclastogen-
esis [9]. RANKL binds to its receptor RANK which is present at
the surface of osteoclast precursors, inducing osteoclast forma-
tion and activation [9,10]. Studies have shown that RAW264.7
cells, one of the osteoclast precursor macrophages, could
differentiate to osteoclasts when cultured in the presence of
RANKL [10]. The major features of osteoclasts include the
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phosphatase (TRAP), and to express proteases including matrix
metalloproteinases (MMPs) which favor cancer invasion and
metastasis [10,11]. Importantly, the expression of RANKL has
also been found in some cancer cells as well as in activated T-
cells [6,11,12]. Therefore, RANKL signaling has been believed
to be a therapeutic target for the inhibition of bone remodeling
and bone metastasis [13].
Moreover, several molecules including endothelin-1, BMP, and
Wnt have been believed as the important regulators for osteoblast
differentiation and bone formation [2,14–16]. The histological
studies have shown that osteoblastic lesions of PCa bone metastasis
are characterized by deposition of new bones, which are produced
by osteoblasts, unorganized and interlaced between foci of cancer
cells. In osteoblasts, endothelin-1, BMP, and the molecules in Wnt
signaling are highly expressed. In addition, elevated serum levels of
bone-specific alkaline phosphatase, a marker of osteoblast
differentiation and proliferation, are often observed in cancer
patient with bone metastasis [17], suggesting the importance of
these molecules in PCa bone metastasis. Therefore, targeting these
osteoblastic molecules could inhibit bone remodeling and PCa
bone metastasis.
Recently, natural agents have received much attention in the
area of cancer research. Isoflavone genistein mainly found in
soybean has shown its ability to inhibit cancer cell growth in vitro
and in vivo without toxicity. We have previously found that
isoflavone genistein could inhibit NF-kB and Akt activation in
cancer cells [18]. Moreover, we have reported that dietary
genistein could inhibit PCa in experimental bone metastasis in a
SCID-human model [19] and that genistein could potentiate
apoptosis inducing effects of chemotherapeutic agents through
down-regulation of NF-kB [20]. 3,39-diindolylmethane (DIM) is
another natural agent and mainly found in the members of the
family Cruciferae such as broccoli. We and others have found that
DIM and its formulated product (BR-DIM manufactured by
BioResponse, LLC. with enhanced bioavailability) could down-
regulate the expression of AR, Akt and NF-kB, leading to the
inhibition of PCa growth and the induction of apoptosis in vitro and
in vivo [21,22]. DIM was also found to potentiate the therapeutic
efficacy of chemotherapeutics [23]. In this study, we investigated
whether isoflavone mixture G2535 containing 70.5% genistein,
and BR-DIM could inhibit the differentiation of osteoclasts and
osteoblasts mediated through regulation of cellular signaling
pathways that are involved in bone remodeling and PCa bone
metastasis.
Results
Differentiation of osteoclasts and osteoblasts in
co-culture system with PCa cells
To investigate the role of bone-related cellular signaling in bone
remodeling during PCa bone metastasis, we first developed a co-
culture system to allow PCa cells and osteoclasts or osteoblasts
grown under the same culture medium condition. We found that
PC-3 prostate cancer cells could grow nicely with pre-osteoclast
(Raw264.7) cells (Figure 1A) and that both C4-2B cells and pre-
osteoblasts (hFOB1.19 cells) could grow together (Figure 1B).
Then, we treated co-culture of PC-3 and RAW264.7 cells with
RANKL or TGF-b to induce osteoclast differentiation. We
incubated the co-culture of C4-2B and hFOB1.19 cells at 39uC
to induce osteoblast differentiation. TRAP staining was conducted
for detecting osteoclast differentiation while alkaline phosphatase
staining was performed for detecting osteoblast differentiation. We
observed formation of multinucleated cells and the dark brown
granules in the differentiated osteoclasts surrounded by PC-3 cells
(Figure 2A), suggesting that the differentiation of osteoclast could
be induced by RANKL or TGF-b in PCa growth environment.
We also observed dark blue granules in hTOB1.19 cells
surrounded by C4-2B cells (Figure 2B), suggesting that osteoblast
could be differentiated when grown together with PCa cells.
TGF-b induced osteoclast differentiation through RANKL
Since we observed differentiation of osteoclast by TGF-b,w e
tested the effect of TGF-b on the expression of RANKL. We
found that the expression level of RANKL was significantly
increased by TGF-b treatment in C4-2B and PC-3 cells
(Figure 3A), suggesting that the induction of osteoclast differen-
tiation by TGF-b was mediated through the up-regulation of
RANKL and that PCa cells could produce RANKL to induce
osteoclast differentiation. We also observed that the expression
level of CXCR-4, one of the critical genes for metastasis, was
significantly increased by TGF-b treatment. These results suggest
that the increased level of TGF-b by tumor or stromal cells could
promote bone remodeling and PCa metatstasis through RANKL
and CXCR-4 signaling.
Co-culture with prostate cancer cells increased the
differentiation of osteoclasts and osteoblasts
To investigate whether PCa cells could promote differentiation
of osteoclasts and osteoblasts, we cultured RAW264.7 or hFOB
cells in the lower chamber of culture system and cultured various
Figure 1. Prostate cancer cell co-culture with osteoclasts or osteoblasts. A. PC-3 cells (indicated by black triangle) were co-cultured with
RAW264.7 cells (indicated by black arrow) in low cell density (a, b) and high cell density (c, d). B. C4-2B cells (indicated by white triangle) were co-
cultured with hFOB1.19 cells (indicated by white arrow) in low cell density (e, f) and high cell density (g, h). 6100.
doi:10.1371/journal.pone.0033011.g001
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the upper chamber so that the secreted proteins from cancer cells
could enter lower chamber from upper chamber through a
membrane with 1 mm pore. Western Blot analysis was conducted
to measure the osteoclast and osteoblast differentiation markers.
We found that co-culture of RAW264.7 cells with PCa cells
increased the expression of TRAcP, one of the major osteoclast
differentiation markers in RAW264.7 cells (Figure 3B). The
expression of fibronectin was also increased when co-cultured with
C4-2B and PC-3 cells (Figure 3B). We also observed increased
expression of RUNX2, one of the osteoblast markers, in
hFOB1.19 cells (Figure 3C). The expression of osteopontin, one
of the important genes for bone remodeling, was also induced
when co-cultured with PCa cells (Figure 3C). These results suggest
that PCa cells could produce some molecules that contribute to the
induction of differentiation of osteoclasts and osteoblasts, causing
bone remodeling.
Isoflavone and BR-DIM inhibited the differentiation of
osteoclasts and osteoblasts
To investigate the effects of isoflavone and BR-DIM on the
differntiation of osteoclasts and osteoblasts, we treated
RAW264.7 or hFOB1.19 cells with 10 to 25 mMG 2 5 3 5o r
BR-DIM during the processes of osteoclast and osteoblast
differentiation. We conducted TRAP or Alkaline phosphatase
staining to detect the differentiation of osteoclasts or osteoblasts.
We observed that TGF-b induced formation of multinucleated
osteoclasts and that isoflavone and BR-DIM treatments signifi-
cantly decreased the dark brown granules in RAW264.7 cells
(Figure 4A) and the dark blue granules in hFOB1.19 cells when
cultured alone (Figure 4B) or co-cultured with C4-2B (Figure 4C).
These results clearly suggest that isoflavone and BR-DIM could
inhibit the differentiation of osteoclasts and osteoblasts, which
could attenuate bone remodeling during PCa metastasis and
would be highly desirable for the inhibition of PCa bone
metastasis.
Isoflavone and BR-DIM regulated RANKL and prostate
cancer signaling, which could inhibit osteoclastogenesis
and prostate cancer growth
Since we found that isoflavone and BR-DIM inhibited the
differentiation of osteoclast, we further investigated the molecular
mechanism of isoflavone and BR-DIM action on osteoclastgenesis.
Figure 2. Differentiation of osteoclasts or osteoblasts. A. RAW264.7 cells were co-cultured with PC-3 cells (indicated by black arrow) and
treated with 100 ng/ml RANKL (a, b) or 10 ng/ml TGF-b (c, d) for 8 days. TRAP staining showed dark brown granules (indicated by white arrow) in
differentiated osteoclasts surrounded by PC-3 cells. B. hFOB1.19 cells were cultured alone (e, f) or co-cultured (g, h) with C4-2B cells (indicated by
black triangle) in 39uC for 5 days. Alkaline phosphatase staining showed dark blue granules (indicated by white triangle) in differentiated osteoblasts.
6200.
doi:10.1371/journal.pone.0033011.g002
Figure 3. Osteoclast or osteoblast marker analysis. A: C4-2B and
PC-3 cells were treated with 100 ng/ml OPG or 10 ng/ml TGF-b for
24 hours. The expression of RANKL and CXCR-4 protein was measured
by Western Blot analysis. B and C: RAW246.7 (B) and hFOB1.19 (C) cells
in lower chambers were co-cultured with C4-2B (C4), PC-3 (PC), ARCaPM
(M) and ARCaPE (E) prostate cancer cells in upper chambers for
48 hours. Western Blot analysis was conducted to measure the
expression of osteoclast or osteoblast markers in RAW264.7 or
hFOB1.19 cells.
doi:10.1371/journal.pone.0033011.g003
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C4-2B cells treated with G2535 or BR-DIM. By using Ingenuity
Pathway Analysis, we found that isoflavone and BR-DIM
inhibited the cellular signal transduction in the RANKL signaling
pathway (Figure 5A and Table 1) and PCa signaling (Figure 5B
and Table 1). BR-DIM and isoflavone significantly inhibited the
expression of MITF, one of the important transcrption factors
involved in the regulation of osteoclastic gene expression
(Figure 5A and Table 1). BR-DIM and isoflavone also inhibited
the signal transductions in PCa signaling with up-regulation of p27
and down-regulation of PSA and cyclin D (Figure 5B and Table 1).
Moreover, isoflavone and BR-DIM regulated the molecules in the
signal transduction networks with down-regulation of Akt, NKX3-
1, STK-4, CDK13 and MITF (Figure 5C, 5D and Table 1),
leading to the inhibition of osteoclastogenesis and PCa growth.
Furthermore, we conducted real-time RT-PCR and Western blot
analysis to confirm the results from microarray and Ingenity
Pathway Analysis. We observed that BR-DIM and isoflavone
down-regulated the expression of MITF, Akt, NKX3-1, cyclin D
and PSA, and up-regulated the expression of p27, p38 and CREB
at the mRNA (Figure 6 A and 6B) and protein (Figure 6C and 6D)
levels. These results are consistant with microarray data,
suggesting that BR-DIM and isoflavone could inhibit osteoclasto-
genesis and PCa growth.
RANKL up-regulated the expression of miR-92a while
isoflavone and BR-DIM abragated the up-regulation of
miR-92a stimulated by RANKL
By computerized prediction of target miRNAs, we found that
RANKL could regulate several miRNAs such as miR-92a and
miR-155, leading to increased osteoclastogenesis. To confirm
whether miR-92a is a legitimate target of RANKL or not, we
treated C4-2B cells with 100 ng/ml RANKL for 24 hours. We
Figure 4. Isoflavone and BR-DIM inhibited the differentiation of osteoclasts and osteoblasts. A: RAW246.7 cells were treated with 10 ng/
ml TGF-b alone or combined with 10 mM G2535 for 8 days. TRAP staining was conducted. Dark brown granules indicated the differentiation of
osteoclasts.6100. B and C: hFOB1.19 cells were cultured alone (B) or co-cultured with C4-2B cells (C) at 39uC. The cells were also treated with 20 mM
G2535 or 10 mM BR-DIM for 5 days. Alkaline phosphatase staining showed dark blue granules in differentiated osteoblasts. 6200.
doi:10.1371/journal.pone.0033011.g004
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networks (C, D) analyzed by microarray and Ingenuity Pathway analysis in C4-2B cells. Red indicates up-regulated molecules while green specifies
down-regulated molecules. The figures were automatically created by Ingenuity Pathway Analysis software.
doi:10.1371/journal.pone.0033011.g005
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PCa cells (Figure 7A). Importantly, we found that treatment of
cells with isoflaone or BR-DIM decreased the expression of miR-
92a and attenuated the induction of miR-92a expression
stimulated by RANKL in PCa cells (Figure 7A), suggesting a
mechanistic link between RANKL, miR-92a and the biological
activity of isoflavones or BR-DIM.
Isoflavone and BR-DIM regulated Epithelial-to-
Mesenchymal Transition (EMT) markers, E-cadherin and
vimentin
Since we observed that isoflavone and BR-DIM could inhibit
the expression of miR-92a which could promote metastasis and
regulate EMT by targeting down-regulation in the expression of
E-cadherin [24], we further investigated the effects of isoflavone
Table 1. BR-DIM and G2535 altered mRNA expression levels measured by microarray.
Gene Probe ID Control BR-DIM G2535
6h 4 8h 6h 7 2h
PSA 204582_s_at 4219.0 3560.0 11.8 134.0 1388.5
PSA precursor 204583_x_at 5095.8 3424.2 14.6 269.5 1544.8
p27 209112_at 1379.1 1781.6 2823.3 1448.2 2046.0
Cyclin D1 208711_s_at 345.9 182.3 231.9 97.8 110.8
Akt1 207163_s_at 2149.0 926.6 894.4 1223.5 1267.4
NKX3.1 209706_at 1765.4 565.9 259.7 247.0 823.7
MITF 207233_s_at 808.6 735.2 382.4 425.4 526.9
CDK13 207318_s_at 1274.7 910.8 958.6 994.6 1058.7
p38 211561_x_at 728.2 777.7 636.2 813.9 492.8
CREB 214513_s_at 573.8 761.5 588.1 686.7 394.9
doi:10.1371/journal.pone.0033011.t001
Figure 6. Gene expressions validated by RT-PCR and Western Blot analysis. BR-DIM and isoflavone regulated the expression of MITF, p38,
Akt, NKX3-1, p27, cyclin D, CREB and PSA at mRNA and protein levels tested by real-time PCR (A, B) and Western Blot analysis (C, D). C4-2B (A, C) and
PC-3 (B, D) cells were treated with 25 mM G2535 or 25 mM BR-DIM for 24 hours (for RNA extraction) or 48 hours (for protein extraction). (BD: BR-DIM).
doi:10.1371/journal.pone.0033011.g006
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two most important and well accepted EMT markers that are
directly associated with EMT phenotype. We cultured C4-2B cells
in the lower chamber of a co-culture system where we cultured
RAW264.7 and hFOB1.19 cells in the upper chamber to mimic
the tumor microenvironment of PCa cells and osteoclast/
osteoblast interaction. Subsequently, we treated the cells with
25 mM G2535 or 25 mM BR-DIM for 48 hours. We found that
isoflavone or BR-DIM treatment increased the expression of E-
cadherin and decreased the expression of vimentin (Figure 7B),
suggesting that isoflavone and BR-DIM could prevent the
induction of EMT by regulating the expression of miR-92a, E-
cadherin and vimentin.
Isoflavone and BR-DIM inhibited the expression of
osteoblastic gene
Since we observed that isoflavone and BR-DIM could inhibit
differentiation of osteoblasts, we further investigated the molecular
target of isoflavone and BR-DIM action on the osteoblast
differentiation. We treated hFOB1.19 cells with 25 mM G2535
or 25 mM BR-DIM for 48 hours. We found that isoflavone or BR-
DIM treatment inhibited the expression of periostin (Figure 7C),
one of the important genes for osteoblast differentiation. These
results suggest that the inhibition of periostin could be one of the
molecular mechanisms by which isoflavone and BR-DIM
inhibited differentiation of osteoblasts.
Discussion
It is well known that PCa cells frequently metastasize to the
bone. In the bone, metastasized PCa cells could utilize the
nutrients from blood in the bone marrow, interact with pre-
osteoclasts and pre-osteoblasts, and stimulate bone remodeling
[25,26]. The interaction between PCa cells and pre-osteoclasts/
pre-osteoblasts is a critical step for bone remodeling during PCa
bone metastasis [26]. Therefore, development of a co-culture
system with PCa cells and pre-osteoclasts/pre-osteoblasts is
important for investigating molecular interactions of signaling
pathways during PCa bone metastasis and bone remodeling. Our
data showed that androgen-insensitive PCa cells including PC-3
and C4-2B cells could grow nicely with pre-osteoclasts or pre-
osteoblasts in the same culture dish with defined medium, which
mimics in vivo environment with direct interaction of PCa cells and
local bone cells. In our co-culture system, PCa cells, pre-
osteoclasts, and pre-osteoblasts could also grow in individual
chambers which were separated by a membrane allowing proteins
(soluble factors) distribution between the two chambers while
separating different types of cells in individual chambers. In this
way, the effect of secreted proteins (soluble factors) from PCa cells
on bone cells or the effects of secreted proteins from bone cells on
PCa cells could be investigated. Using co-culture, we tested the
molecular alterations in osteoclasts or osteoblasts stimulated by
PCa cells. Recent studies by other investigators showed that co-
culture of osteoclast and osteoblast could be useful for examining
bone metabolism and osteoclastogenesis [27,28]. These findings
suggest that the co-culture system is very useful for investigating
the molecular alterations when PCa cells are homing to the bone,
which will allow for assessing alterations in the signal transductions
between PCa cells and the local bone cells during PCa bone
metastasis and bone remodeling as documented by our results.
The differentiation of osteoclasts or osteoblasts is an important
step during cancer metastasis to the bone and bone remodeling. By
using our co-culture system, we found that pre-osteoclasts could
differentiate in to mature osteoclast when co-cultured together
with PCa cells. In addition, pre-osteoblasts could also differentiate
in to mature osteoblast when co-cultured with PCa cells.
Furthermore, we found that co-culture of osteoclasts and
osteoblasts with PCa cells could increase the differentiation of
osteoclasts and osteoblasts. These findings suggest that the
molecules produced by PCa cells could induce the differentiation
of osteoclasts and osteoblasts. Importantly, we found that
isoflavone and BR-DIM could inhibit the differentiation of
osteoclasts and osteoblasts when co-cultured with PCa cells,
suggesting that isoflavone and BR-DIM would be useful for the
Figure 7. Isoflavone and BR-DIM regulated miRNAs, EMT and
osteoblast markers. A: C4-2B cells were treated with 100 ng/ml
RANKL, 25 mM G2535, 25 mM BR-DIM, or combination of RANKL and
G2535 or BR-DIM for 24 hours. Total RNA was extracted and the
expression of miR-92a was detected in treated C4-2B cells. B: C4-2B cells
were cultured in lower chamber of co-culture system. RAW246.7 and
hFOB1.19 cells were cultured in upper chamber. The cells were treated
with 25 mM G2535 or 25 mM BR-DIM for 48 hours. The expression of E-
cadherin and vimentin was measured by Western Blot analysis. C:
hFOB1.19 cells were treated with 25 mM G2535 or 25 mM BR-DIM for
48 hours. The expression of periostin was detected by Western Blot
analysis.
doi:10.1371/journal.pone.0033011.g007
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It has been known that PCa cells in bone metastasis stimulate bone
remodeling while bone remodeling facilitates PCa bone metastasis
and invasion in the bone [29–31], which is known as a vicious
cycle of bone remodeling and bone metastasis. Our results showed
that isoflavone and BR-DIM inhibited bone cell differentiation,
suggesting that isoflavone and BR-DIM could inhibit PCa bone
metastasis through disrupting bone remodeling.
It has been reported that differentiation of osteoclasts occurs
first during bone remodeling when PCa cells metastasize to the
bone [4,5]. Therefore, inhibition of osteoclast differentiation is
important for interrupting PCa bone metastasis and homing. It is
well known that RANK/RANKL/OPG signaling is key regulator
for osteoclast differentiation [32]. Our results showed that
RANKL treatment could significantly induce differentiation of
osteoclast, which is consistent with published report [33]. More
importantly, we found that TGF-b could up-regulate the
expression of RANKL, leading to the differentiation of osteoclasts.
These results are also consistent with report from other
investigator [31], suggesting that the activation of TGF-b, which
is commonly seen in advanced PCa, could stimulate the
differentiation of osteoclasts, leading to bone resorption and bone
remodeling. Moreover, it is well known that TGF-b could also
induce EMT [34], which facilitates PCa progression including
invasion and bone metastasis. Importantly, our data showed that
isoflavone could attenuate TGF-b induced osteoclast differentia-
tion, and that isoflavone and BR-DIM could regulate the
expression of EMT markers (Figure 8), suggesting that these
natural agents could be useful for the prevention of PCa
progression and bone metastasis.
Emerging evidence suggest that microRNAs (miRNAs) regulate
many physiological and pathological processes [35]. Our results
showed that in addition to regulating osteoclasts, RANKL could
also up-regulate the expression of miR-92a. The miR-92a has
been found to down-regulate the expression of anti-tumor genes,
resulting in cancer cell proliferation [36]. Recent report showed
that E-cadherin is a direct target of miR-92a and that the
expression of miR-92a promoted lymph node metastasis of human
esophageal squamous cell carcinoma via down-regulation of E-
cadherin [24]. Therefore, RANKL could also promote PCa
progression via up-regulation of miR-92a and consequently by
down-regulation of E-cadherin. Interestingly, isoflavone and BR-
DIM were able to attenuate the up-regulation of miR-92a
stimulated by RANKL treatment, suggesting the importance of
these natural agents (isoflavone and BR-DIM) in the inhibition of
PCa progression and bone metastasis (Figure 8).
In addition to the inhibitory effects on osteoclasts, isoflavone
and BR-DIM also inhibted the differentiation of osteoblast with
down-regulation of periostin, one of the important genes for
osteoblast differentiation. Therefore, by targeting both osteoclast
and osteoblast differentiation, isoflavone and BR-DIM could
effectively interrupt bone remodeling, providing unfavorable
micoenvironment for the homing of PCa cells to the bone.
Although both isoflavone and BR-DIM showed inhibitory effects
on bone cell differentation, the involved molecules and altered
levels by isoflavone or BR-DIM treatment were not the same,
suggesting that complex regulatory mechanisms are involved. By
pathway and network analysis, we found that isoflavone and BR-
DIM could affect multiple signaling pathways such as AR/PSA,
NKX3-1/Akt/p27, LEF1/cyclin D1, MITF/NR3C1, etc. In BR-
DIM treated C4-2B cells, we found more potent down-regulation
of PSA which has been found to modulate genes involved in bone
remodeling and osteoblast differentiation [37]. These results
suggest the multi-targeting effects of isoflavone and BR-DIM,
which will make isoflavone and BR-DIM powerful agents for
inhibiting PCa growth in bone microenvironment.
In conclusion, isoflavone and BR-DIM were able to target both
osteoclast and osteoblast differentiation, and also could target
multiple molecules in PCa cells; therefore, these agents could
inhibit bone remodeling and PCa growth, suggesting that
isoflavone and BR-DIM could be very useful for the prevention
of PCa progression, especially bone metastasis. The biological
activity of isoflavone and BR-DIM is mediated through the down-
regulation of multiple signaling pathways including RANKL, AR/
PSA, and Akt signaling, which makes them very promising agents
for the prevention and/or treatment of PCa and its bone
metastasis in combination with conventional chemotherapy.
Materials and Methods
Cell lines, reagents, and antibodies
PC-3 (ATCC, Manassas, VA), C4-2B, ARCaPE and ARCaPM
(Novicure, Birmingham, AL) prostate cancer cells and pre-
osteoclast RAW264.7 (ATCC) cells were maintained in RPMI
1640 (Invitrogen, Carlsbad, CA) supplemented with 10% fetal
bovine serum, 50 U/ml penicillin, and 50 mg/ml streptomycin in
a5 %C O 2 atmosphere at 37uC. Pre-osteoblast hFOB1.19 (ATCC)
cells were maintained in DMEM/F12 without phenol red
(Invitrogen) supplemented with 10% fetal bovine serum, 50 U/
ml penicillin, and 50 mg/ml streptomycin in a 5% CO2
atmosphere at 34uC. Isoflavone mixture G2535 (70.5% genistein,
26.3% daidzein and 0.31% glycetein manufactured by Organic
Technologies and obtained from NIH) was dissolved in DMSO to
make a stock solution containing 50 mM genistein. The
concentrations of isoflavone we described in this article all refer
to the concentration of genistein in isoflavone mixture. BR-DIM
(BioResponse, LLC., Boulder, CO; formulated-DIM with higher
bioavailability in vivo [38]) was generously provided by Dr. Michael
Zeligs and was dissolved in DMSO to make a 50 mM stock
solution. Anti-CXCR-4 (Santa Cruz, Santa Cruz, CA), anti-
fibronectin (Santa Cruz), anti-RUNX2 (Santa Cruz), anti-
osteopontin (Santa Cruz), anti-periostin (Santa Cruz), anti-E-
cadherin (Santa Cruz), anti-vimentin (Dako), anti-RANKL (R&D,
Danvers, MA), anti-TRAcP (Sigma, St. Louis, MO), anti-MITF
(Santa Cruz), anti-p27 (Santa Cruz), anti-PSA (Santa Cruz), anti-
Figure 8. Diagram of isoflavone and BR-DIM regulated bone
cell differentiation, bone remodeling, EMT, and PCa bone
metastasis.
doi:10.1371/journal.pone.0033011.g008
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and anti-GAPDH (Sigma) primary antibodies were used for
Western Blot analysis.
Co-culture of PCa cells with osteoclasts and osteoblasts
To emulate PCa cell grown in an osteoclastic environment, PC-
3 cells and RAW264.7 cells were co-cultured at 1:1 ratio in RPMI
1640 supplemented with 10% fetal bovine serum, 50 U/ml
penicillin, and 50 mg/ml streptomycin in a 5% CO2 atmosphere
at 37uC. The cells were treated with 100 ng/ml RANKL or
10 ng/ml TGF-b for 8 days to stimulate RAW264.7 cell
differentiation. Likewise, to mimic PCa cell grown in osteoblastic
environment, C4-2B and hFOB1.19 cells were co-cultured at 1:2
ratio in RPMI 1640/F12 (1:1) supplemented with 10% fetal
bovine serum, 50 U/ml penicillin, and 50 mg/ml streptomycin in
a 5% CO2 atmosphere at 39uC for 5 days to stimulate osteoblast
differentiation of hFOB1.19 cells. Moreover, to investigate the
effects of secreted proteins (soluble factors) from one type of cells
on to another type of cells, PC-3 or C4-2B PCa cells were cultured
in 6 well plate (lower chamber) with RAW264.7 or hFOB1.19 cells
grown in cell culture inset (upper chamber, BD Biosciences,
Bedford, MA) which has a membrane with 1.0 mm pores opening
to lower chamber so that the protein secreted from cells can diffuse
to lower chamber while the two types of cells are separated in the
lower or upper chambers.
TRAP staining for testing osteoclast differentiation
RAW264.7 cells or co-culture of RAW264.7 and PC-3 cells
were treated with 100 ng/ml RANKL or 10 ng/ml TGF-b for
RAW264.7 cells differentiating to osteoclasts. After 8 days of
treatment, the formed TRAP in differentiated osteoclasts was
stained using TRAP Staining Kit (Sigma) according to the
manufacturer’s protocol. The purplish to dark brown granules,
which indicate the formation of TRAP, were photographed as
reported in our earlier publication [39].
Alkaline staining for testing osteoblast differentiation
hFOB1.19 or co-culture of hFOB1.19 and C4-2B cells were
incubated at 39uC for 5 days. The alkaline phosphatase in
differentiated osteoblasts was stained using Alkaline Phosphatase
Staining Kit (Sigma) according to the manufacturer’s protocol. In
human bone, alkaline phosphatase activity is restricted to mature
osteoblasts. After staining, the blue and dark blue granules, which
indicate the presence of alkaline phosphatase, in differentiated
osteoblasts were photographed.
Preparation of total lysates and Western Blot analysis
PC-3, C4-2B, ARCaPE, ARCaPM, RAW264.7, and hFOB1.19
cells with or without treatments were lysed in RIPA buffer. After
centrifugation, the concentration of total protein was measured
using BCA protein assay (PIERCE, Rockford, IL). Whole cell
lysates were subjected to standard Western Blot analysis as
described previously [39]. The signal was then detected using the
chemiluminescent detection system (PIERCE, Rockford, IL).
Microarray analysis of isoflavone and BR-DIM treated PCa
cells
C4-2B cells were treated with 25 mM G2535 for 6 and 72 hours
or 25 mM BR-DIM for 6 and 48 hours. Total RNA from each
sample was isolated by using Trizol (Invitrogen) and purified by
using RNeasy Mini Kit and RNase-free DNase Set (QIAGEN,
Valencia, CA) according to the manufacture’s protocols. cDNA
for each sample was synthesized by using Superscript cDNA
Synthesis Kit (Invitrogen, Carlsbad, CA). Then, the biotin-labeled
cRNA was transcripted in vitro (IVT) from cDNA by using
BioArray HighYield RNA Transcript Labeling Kit (ENZO
Biochem, New York, NY), and purified by RNeasy Mini Kit.
The purified cRNA was fragmented and the fragmented labeled
cRNA was applied to Human Genome U133 Plus 2.0 Array
(Affymetrix, Santa Clara, CA). After washing and staining, the
arrays were scanned by using HP GeneArray
TM Scanner
(Hewlett-Packard, Palo Alto, CA). The gene expressions levels of
samples were normalized and analyzed by using Microarray Suite,
MicroDB
TM, and Data Mining Tool software (Affymetrix, Santa
Clara, CA). All data is MIAME compliant and the raw data has
been deposited in GEO database. The GEO accession number is
GSE35324.
Ingenuity pathway analysis for assessing the effects of
isoflavone and BR-DIM on PCa cells
The data from microarray chip were further analyzed for
revealing the pathways that are altered by isoflavone or BR-DIM
treatment. Signaling pathways altered were analyzed using
Ingenuity software (Ingenuity Systems, Redwood City, CA).
Potential intracellular signaling pathways or molecule networks
affected by BR-DIM treatment were identified using the Ingenuity
Pathway Analysis (IPA) software. The significantly altered
canonical pathways and predicted molecule networks were
automatically created and integrated with microarray results by
IPA software.
Total RNA extraction, miRNA and mRNA detection
Total RNA was extracted by using the miRNeasy Mini Kit and
RNase-free DNase Set (QIAGEN, Valencia, CA) following the
protocol provided by the manufacturer. Briefly, the cells from each
treatment were lysed using QIAzol Lysis reagent. After addition of
chloroform, the sample was separated into aqueous and organic
phases by centrifugation. The upper aqueous phase was extracted
and ethanol was added. The sample was then applied to the
RNeasy Mini spin column, where the total RNA including
Table 2. The sequences of primers used for real-time PCR.
Gene Sequence
MITF F: CCAGGCATGAACACACATTC
R: TCCATCAAGCCCAAGATTTC
p27 F: CAGGTAGTTTGGGGCAAAAA
R: ACAGCCCGAAGTGAAAAGAA
Akt F: TCTATGGCGCTGAGATTGTG
R: CTTAATGTGCCCGTCCTTGT
Cyclin D F: GATCAAGTGTGACCCGGACT
R: TCCTCCTCTTCCTCCTCCTC
NKX3.1 F: CCAGGCTTACTGAGCTGTCC
R: GCAAAAGGCTCACTCAGTCC
CREB F: CGACCAGCTGTGTCTGATGT
R: ATATCCCCTCCCCTTTCCTT
p38 F: TGCACATGCCTACTTTGCTC
R: AGGTCAGGCTTTTCCACTCA
PSA F: ATTCCGCCGGAGAGCTGTGTC
R: TCTCGCACTCCCAGCCTCCC
doi:10.1371/journal.pone.0033011.t002
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protein, and other contaminants were washed away, and high
quality RNA was then eluted in RNase-free water.
The expression level of miR-92a in RANKL, isoflavone and
BR-DIM treated C4-2B cells was analyzed by using TaqMan
MicroRNA Assay Kit (Applied Biosystems, Foster City, CA)
following manufacturer’s protocol. Briefly, five nano-gram of total
RNA from each sample was subjected to reverse transcription with
a specific miRNA primer (Applied Biosystems). Real-time PCR
reactions were then carried out in a total volume of 10 ml reaction
mixture including RT product, 206TaqMan miRNA Assay mix,
26 TaqMan PCR Master Mix, and dH2O in StepOnePlus
(Applied Biosystems). The PCR program was initiated by 10 min
at 95uC before 40 thermal cycles, each of 15 s at 95uC and 1 min
at 60uC. Data were analyzed according to the comparative Ct
method and were normalized by RNU48 and RNU44 expression
in each sample.
The expression level of MITF, p27, Akt, cyclin D, NKX3-1,
CREB, p38, AR and PSA in isoflavone and BR-DIM treated PCa
cells was analyzed by real-time RT-PCR using High Capacity
RNA-to-cDNA Kit and SYBR Green Master Mixture from
Applied Biosystems. The sequences of primers are shown in
Table 2. The PCR was initiated by 10 min at 95uC before 40
thermal cycles, each of 15 s at 95uC and 1 min at 60uC. Data were
analyzed according to the comparative Ct method and were
normalized by GAPDH expression in each sample.
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